Merck
  • Home
  • Search Results
  • The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice.

The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice.

Cardiovascular research (2009-07-14)
Gianluca Grassia, Marcella Maddaluno, Angelo Guglielmotti, Giorgina Mangano, Giuseppe Biondi, Pasquale Maffia, Armando Ialenti
ABSTRACT

Bindarit is an original compound with peculiar anti-inflammatory activity due to a selective inhibition of a subfamily of inflammatory chemokines, including the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8. In this study, we investigated the effect of bindarit on neointima formation using two animal models of arterial injury: rat carotid artery balloon angioplasty and wire-induced carotid injury in apolipoprotein E-deficient (apoE(-/-)) mice. Treatment of rats with bindarit (200 mg/kg/day) significantly reduced balloon injury-induced neointima formation by 39% at day 14 without affecting re-endothelialization and reduced the number of medial and neointimal proliferating cells at day 7 by 54 and 30%, respectively. These effects were associated with a significant reduction of MCP-1 levels both in sera and in injured carotid arteries of rats treated with bindarit. In addition, in vitro data showed that bindarit (10-300 microM) reduced rat vascular smooth muscle cell (VSMC) proliferation, migration, and invasion, processes contributing to the injury-induced neointima formation in vivo. Similar results were observed in hypercholesterolaemic apoE(-/-) mice in which bindarit administration resulted in a 42% reduction of the number of proliferating cells at day 7 after carotid injury and in a 47% inhibition of neointima formation at day 28. Analysis of the cellular composition in neointimal lesions of apoE(-/-) mice treated with bindarit showed that the relative content of macrophages and the number of VSMCs were reduced by 66 and 30%, respectively, compared with the control group. This study demonstrates that bindarit is effective in reducing neointima formation in both non-hyperlipidaemic and hyperlipidaemic animal models of vascular injury by a direct effect on VSMC proliferation and migration and by reducing neointimal macrophage content. All of these data were associated with the inhibition of MCP-1 production.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Actin, α-Smooth Muscle - FITC antibody, Mouse monoclonal, clone 1A4, purified from hybridoma cell culture
Sigma-Aldrich
ECO TWEEN® 20, viscous liquid
Sigma-Aldrich
Anti-PCNA Antibody, clone PC10, clone PC10, Chemicon®, from mouse
Sigma-Aldrich
Evans Blue, Dye content ≥75 %
Sigma-Aldrich
TWEEN® 20, viscous liquid
Sigma-Aldrich
TWEEN® 20, viscosity 250-450 mPa.s (25 °C)
Sigma-Aldrich
TWEEN® 20, for molecular biology, viscous liquid
Sigma-Aldrich
TWEEN® 20, Low-peroxide; Low-carbonyls
Sigma-Aldrich
TWEEN® 20, BioXtra, viscous liquid
Sigma-Aldrich
TWEEN® 20, viscous liquid, suitable for cell culture
Sigma-Aldrich
TWEEN® 20, Low-peroxide; Low-carbonyls
Sigma-Aldrich
Serum Triglyceride Determination Kit,  kit sufficient for 250 tests